NewsRoom Articles - Page 71 of 74 - CanadianCannabisWire

ThursdayAug 31, 2017 3:34 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Begins Laboratory Venture with National Research Council

Collaborative venture could lead to strengthening of company’s patent portfolio, new commercial opportunities Firm receives patent in Australia, anticipates entering that market through cannabinoid licensing arrangements and product distribution partnerships LXRP names Allan Spissinger acting chief financial officer Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has begun laboratory work with the National Research Council ("NRC") (http://cnw.fm/Lp8bB). The collaboration will begin studies using LXRP’s patented technologies. The research will include the company’s technology in vitamins, NSAIDs, nicotine and cannabinoids utilizing lipophilic active agents. LXRP has patented technology involving how those agents are ingested into the human body in various edibles, such…

TuesdayAug 29, 2017 3:52 pm

ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Ensuring Quality of Medical Cannabis Products with Proprietary Growing Technology

Environmentally-controlled growing chambers generate consistent, superior quality Proprietary technologies eliminate risk, ensuring patients enjoy peace of mind Publicly-traded ABcann entered funding deal for $15 million at $2.25 per share The Canadian government’s recent announcement that Broken Coast Cannabis Ltd. is recalling several products sold last year after two banned pesticides were found in random samples illustrates the importance of ABcann Global Corp.’s (TSX.V: ABCN) (OTCQB: ABCCF) controlled, pesticide-free approach to growing medical marijuana (http://nnw.fm/VM7zD). Several other cannabis-growing Canadian companies also reaped the attention of authorities following mandatory testing. Hydropothecary and Peace Naturals both had products recalled earlier this year following…

FridayAug 25, 2017 9:23 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Continues to Deliver Results with its Patented Technology

19 patent applications filed in the United States and internationally (under the Patent Cooperation Treaty), with national filings in 44 countries Collaborative research and development agreement with Canada’s National Research Council to investigate opportunities associated with bioavailability enhancement of certain compounds, including those in cannabinoids, vitamins, NSAIDs and nicotine Out-licenses its patented technology to third party partners, with several deals signed or pending When Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) researchers tackled the issue facing consumers of edible cannabinoids – poor absorption of the product’s bioactive compounds by the body’s gastrointestinal tract – an important statement led the way:…

ThursdayAug 24, 2017 3:22 pm

ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Licensed to Grow Cannabis by Feds in Canada

An early mover in the Canadian cannabis space Serving Canada’s most populous province New funding deal signed for $15 million at $2.25 per share As befits its status as a first mover in the Canadian cannabis space, ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) is racing ahead with plans to supply the medical marijuana needs of Canada’s most populous province. Construction plans at its Kimmett facility in the third quarter of 2017 remain on schedule, and the previously announced plans for a 71,000 square foot phase 1 project have been expanded to 100,000 square feet. The company recently signed a…

MondayAug 14, 2017 5:00 pm

ABcann Global Corporation (TSX.V: ABCN) (OTCQB: ABCCF) Looks Strong for Investors in Booming Canadian Cannabis Market

ABcann’s low current market cap compared to similar companies offers an obvious opportunity for investors ABcann Global is one of Canada’s most dominant growers of medical marijuana and one of the growers to meet Canadian government’s stringent licensing requirements Major expansion of ABcann’s production capacity is underway An interesting opportunity for investors can be found in ABcann Global Corporation (TSX.V: ABCN) (OTCQB: ABCCF), a Canadian grower of medical marijuana. ABcann recently acquired ABcann Medicinals and boasts a recent IPO, appointment of a new medical consultant, and major expansion plans. ABcann is new to the public market, having launched its initial…

MondayJul 24, 2017 12:06 pm

InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Aims at Future of Cannabinoid Compound Treatment

Specializing in novel cannabinoid drug therapies, InMed Pharmaceuticals is well-poised for cannabinoid research and development of new treatments Glaucoma and skin disease pharmaceuticals now in development have an estimated $7.6 billion potential market InMed Pharmaceutical’s chief medical officer helped $3 billion GW Pharmaceuticals develop one of the first cannabis-based drugs With its proprietary bioinformatics assessment tool, cannabinoid biosynthesis technology and drug development pipeline, InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) is well-positioned to target the future of cannabinoid pharmaceutical compounds. InMed is a pre-clinical stage biopharmaceutical company specializing in the development of novel therapies through research and development of the…

TuesdayJul 18, 2017 2:39 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Well-positioned For Expanding Canadian Cannabinoid Market

Lexaria Bioscience Corp. well-positioned for growth in expanding Canadian cannabinoid market Canadian market for cannabis extracts and oils expected to top C$1.6 billion by 2020 Company’s patented technology infuses organically sourced hemp oil into molecules of other substances such as lipids, the basis of the human endocannabinoid system Patented technology enables better-tasting hemp oil-infused gourmet food products with improved bioavailability of cannabinoids Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) is well-positioned for growth in the emerging Canadian cannabinoid market. Lexaria is an innovative revenue-generating company developing and out-licensing proprietary technology for delivering bioactive compounds including cannabinoids. With full legalization expected…

WednesdayJul 12, 2017 12:48 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) is “One to Watch”

Revenue-generating biosciences company focused on improving the delivery of bioactive compounds through gourmet foods Proprietary technology shown to enhance the bioavailability of orally ingested cannabinoids while improving the taste Actively developing and selling hemp oil-based gourmet food products through consumer brands ViPova™ and Lexaria Energy Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. Though boasting a wide range of health benefits, cannabinoids are traditionally poorly absorbed by the body’s gastrointestinal tract. To achieve higher effectiveness, consumers usually default to smoking. Lexaria provides a…

ThursdayJul 06, 2017 2:55 pm

Invictus MD (TSX.V: IMH) (OTC: IVITF) Poised to Have First-Mover Advantage in Canada’s Legal Cannabis Market

One of few Canadian cannabis companies to declare dividends Poised for first-mover advantage in Canada’s legal marijuana market 250 acres of cultivation space spanning from Alberta to Ontario Retail sales in Canada’s recreational marijuana market could climb to $6.0 billion by 2021, according to Deloitte Canadian, and Invictus MD Strategies Corp. (TSX.V: IMH) (OTC: IVITF) is strategically positioned to grow right alongside this burgeoning market and gain first-mover advantage as soon as Canada’s cannabis market is freed up by the necessary legislative regulations. Founded in Vancouver, Canada, Invictus MD is a cannabis company that is dedicated to offering high-quality, regulated…

WednesdayJul 05, 2017 12:45 pm

InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Focused on the Science of Cannabinoids

Science-based cannabinoid pharmaceuticals are big market winners InMed Pharmaceuticals is developing two potential blockbuster drugs IMLFF has innovative and disruptive market advantages The market is rife with hype, pretenders and wannabes in the booming cannabis markets. In the rush to find the next hot cannabis stock, investors often overlook the real value in long-term scientific applications, and, after the heady hoopla of once-illicit marijuana dies down, those that chose science will be the ultimate winners. The medicinal and scientific applications of the 90 individual cannabinoid drugs found in cannabis are where the real value lies. Look no further than GW…

News and Publishing Service for Cannabis Related, Canadian Companies

Contact us: 905.674.5977